Eric Padron, MD

Generally, my clinical interests are the care and treatment of patients with adult myeloid malignancies including MDS, AML and Myeloproliferative Neoplasms (MPNs) with a specific interest in the Myeloproliferative/Myelodysplastic (MDS/MPN) syndromes of which CMML is a member.

Provider

Eric Padron, MD

Medical Oncology

Call 1-888-Moffitt
(1-888-663-3488)
For an Appointment

Schedule Appointment

Program
Malignant Hematology

Print Print Physician Bio

Education & Training

BOARD CERTIFICATION:
  • Medical Oncology
FELLOWSHIP:
  • Moffitt Cancer Center - Hematology/Oncology
RESIDENCY:
  • University of Florida Shands Hospital -
MEDICAL SCHOOL:
  • University of Florida - MD
Provider

Eric Padron, MD

Medical Oncology

Call 1-888-Moffitt
(1-888-663-3488)
For an Appointment

Schedule Appointment

Program
Malignant Hematology

Print Print Physician Bio

Publications

  • Sallman DA, Komrokji R, List A, Padron E. Reply to Goel et al. 'TP53 mutation allele-burden and disease outcome in MDS/AML'. Leukemia. 2017 Mar;31(3):767-768. Pubmedid: 27740632.
  • Griffin PT, Komrokji RS, Sweet K, Al Ali NH, Padron E, Kubal TE, List AF, Lancet JE. Bone marrow cellularity at day 14 is the most important predictive factor for response in patients with AML who require double-induction chemotherapy: Analysis from a large, single institution experience. Am J Hematol. 2017 Mar;92(3):232-237. Pubmedid: 28006850.
  • Nassereddine S, Nishihori T, Padron E, Mahfouz R, Bazarbachi A, Komrokji RS, Kharfan-Dabaja MA. Integrating Genomics in Myelodysplastic Syndrome to Predict Outcomes After Allogeneic Hematopoietic Cell Transplantation. Clin Lymphoma Myeloma Leuk. 2017 Jan;17(1):7-13. Pubmedid: 27771290.
  • Apuri S, Al Ali N, Padron E, Lancet JE, List AF, Komrokji RS. Evidence for Selective Benefit of Sequential Treatment With Hypomethylating Agents in Patients With Myelodysplastic Syndrome. Clin Lymphoma Myeloma Leuk. 2017 Jan. Pubmedid: 28185797.
  • Gillis NK, Ball M, Zhang Q, Ma Z, Zhao Y, Yoder SJ, Balasis ME, Mesa TE, Sallman DA, Lancet JE, Komrokji RS, List AF, McLeod HL, Alsina M, Baz R, Shain KH, Rollison DE, Padron E. Clonal haemopoiesis and therapy-related myeloid malignancies in elderly patients: a proof-of-concept, case-control study. Lancet Oncol. 2017 Jan;18(1):112-121. Pubmedid: 27927582.
  • Badar T, Johnson L, Trifilo K, Wang H, Kudlow BA, Padron E, Pappenhausen PR, Hussaini MO. Detection of Novel t(12;17)(p12;p13) in Relapsed Refractory Acute Myeloid Leukemia by Anchored Multiplex PCR(AMP)-based Next-Generation Sequencing. Appl Immunohistochem Mol Morphol. 2017 Feb. Pubmedid: 28187034.
  • Talati C, Zhang L, Shaheen G, Kuykendall A, Ball M, Zhang Q, Lancet JE, Zuckerman KS, List AF, Komrokji R, Moscinski L, Padron E. Monocyte subset analysis accurately distinguishes CMML from MDS and is associated with a favorable MDS prognosis. Blood. 2017 Feb. Pubmedid: 28159734.
  • Knepper TC, Bell GC, Hicks JK, Padron E, Teer JK, Vo TT, Gillis NK, Mason NT, McLeod HL, Walko CM. Key Lessons Learned from Moffitt's Molecular Tumor Board: The Clinical Genomics Action Committee Experience. Oncologist. 2017 Feb;22(2):144-151. Pubmedid: 28179575.
  • Zeidan AM, Al Ali N, Barnard J, Padron E, Lancet JE, Sekeres MA, Steensma DP, DeZern A, Roboz G, Jabbour E, Garcia-Manero G, List A, Komrokji R. Comparison of clinical outcomes and prognostic utility of risk stratification tools in patients with therapy-related vs de novo myelodysplastic syndromes: a report on behalf of the MDS Clinical Research Consortium. Leukemia. 2017 Feb. Pubmedid: 28111463.
  • Sallman DA, Padron E. Integrating mutation variant allele frequency into clinical practice in myeloid malignancies. Hematol Oncol Stem Cell Ther. 2016 Sep;9(3):89-95. Pubmedid: 27187622.
  • Coombs CC, Sallman DA, Devlin SM, Dixit S, Mohanty A, Knapp K, Al Ali NH, Lancet JE, List AF, Komrokji RS, Padron E, Arcila ME, Klimek VM, van den Brink MR, Tallman MS, Levine RL, Rampal RK, Rapaport F. Mutational correlates of response to hypomethylating agent therapy in acute myeloid leukemia. Haematologica. 2016 Nov;101(11):e457-e460. Pubmedid: 27418649.
  • Ball M, List AF, Padron E. When clinical heterogeneity exceeds genetic heterogeneity: thinking outside the genomic box in chronic myelomonocytic leukemia. Blood. 2016 Nov;128(20):2381-2387. Pubmedid: 27707735.
  • Komrokji RS, Kulasekararaj A, Al Ali NH, Kordasti S, Bart-Smith E, Craig BM, Padron E, Zhang L, Lancet JE, Pinilla-Ibarz J, List AF, Mufti GJ, Epling-Burnette PK. Autoimmune diseases and myelodysplastic syndromes. Am J Hematol. 2016 May;91(5):E280-E283. Pubmedid: 26875020.
  • Sallman DA, Komrokji R, Vaupel C, Cluzeau T, Geyer SM, McGraw KL, Al Ali NH, Lancet J, McGinniss MJ, Nahas S, Smith AE, Kulasekararaj A, Mufti G, List A, Hall J, Padron E. Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes. Leukemia. 2016 Mar;30(3):666-673. Pubmedid: 26514544.
  • Suleiman Y, Dalia S, Liu JJ, Bowers JW, Padron E, Lancet JE, Fulp W, Moscinski LC, Komrokji RS, Zuckerman KS, Zhang L. Clinical prognostic factors and outcomes of essential thrombocythemia when transformed to myelodysplastic syndromes and acute myeloid leukemia. Leuk Res. 2016 Mar;42:52-58. Pubmedid: 26894965.
  • Rollison DE, Shain KH, Lee JH, Hampras SS, Fulp W, Fisher K, Al Ali NH, Padron E, Lancet J, Xu Q, Olesnyckyj M, Kenvin L, Knight R, Dalton W, List A, Komrokji RS. Subsequent primary malignancies and acute myelogenous leukemia transformation among myelodysplastic syndrome patients treated with or without lenalidomide. Cancer Med. 2016 Jul;5(7):1694-1701. Pubmedid: 27098006. Pmcid: PMC4944897.
  • Merlevede J, Droin N, Qin T, Meldi K, Yoshida K, Morabito M, Chautard E, Auboeuf D, Fenaux P, Braun T, Itzykson R, de Botton S, Quesnel B, Commes T, Jourdan E, Vainchenker W, Bernard O, Pata-Merci N, Solier S, Gayevskiy V, Dinger ME, Cowley MJ, Selimoglu-Buet D, Meyer V, Artiguenave F, Deleuze JF, Preudhomme C, Stratton MR, Alexandrov LB, Padron E, Ogawa S, Koscielny S, Figueroa M, Solary E. Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia responding to hypomethylating agents. Nat Commun. 2016 Feb;7:10767. Pubmedid: 26908133. Pmcid: PMC4770084.
  • Mesa R, Jamieson C, Bhatia R, Deininger MW, Gerds AT, Gojo I, Gotlib J, Gundabolu K, Hobbs G, Klisovic RB, Kropf P, Mohan SR, Oh S, Padron E, Podoltsev N, Pollyea DA, Rampal R, Rein LA, Scott B, Snyder DS, Stein BL, Verstovsek S, Wadleigh M, Wang ES, Bergman MA, Gregory KM, Sundar H. Myeloproliferative Neoplasms, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Ne. 2016 Dec;14(12):1572-1611. Pubmedid: 27956542.
  • Basiorka AA, McGraw KL, Eksioglu EA, Chen X, Johnson J, Zhang L, Zhang Q, Irvine BA, Cluzeau T, Sallman DA, Padron E, Komrokji R, Sokol L, Coll RC, Robertson AA, Cooper MA, Cleveland JL, O'Neill LA, Wei S, List AF. The NLRP3 inflammasome functions as a driver of the myelodysplastic syndrome phenotype. Blood. 2016 Dec;128(25):2960-2975. Pubmedid: 27737891. Pmcid: PMC5179338.
  • Talati C, Padron E. An Exercise in Extrapolation: Clinical Management of Atypical CML, MDS/MPN-Unclassifiable, and MDS/MPN-RS-T. Curr Hematol Malig Rep. 2016 Dec;11(6):425-433. Pubmedid: 27664113.
  • Haider M, Al Ali N, Padron E, Epling-Burnette P, Lancet J, List A, Komrokji R. Immunosuppressive Therapy: Exploring an Underutilized Treatment Option for Myelodysplastic Syndrome. Clin Lymphoma Myeloma Leuk. 2016 Aug;16 Suppl:S44-S48. Pubmedid: 27521323.
  • Grabska J, Shah B, Reed D, Al Ali N, Padron E, Ramadan H, Lancet J, List A, Komrokji R. Myelodysplastic Syndromes in Adolescent Young Adults: One Institution's Experience. Clin Lymphoma Myeloma Leuk. 2016 Aug;16 Suppl:S53-S56. Pubmedid: 27521325.
  • Ramadan H, Duong VH, Al Ali N, Padron E, Zhang L, Lancet JE, List AF, Komrokji RS. Eltrombopag Use in Patients With Chronic Myelomonocytic Leukemia (CMML): A Cautionary Tale. Clin Lymphoma Myeloma Leuk. 2016 Aug;16 Suppl:S64-S66. Pubmedid: 27521328.
  • Padron E, Dezern A, Andrade-Campos M, Vaddi K, Scherle P, Zhang Q, Ma Y, Balasis ME, Tinsley S, Ramadan H, Zimmerman C, Steensma DP, Roboz GJ, Lancet JE, List AF, Sekeres MA, Komrokji RS. A Multi-Institution Phase I Trial of Ruxolitinib in Patients with Chronic Myelomonocytic Leukemia (CMML). Clin Cancer Res. 2016 Aug;22(15):3746-3754. Pubmedid: 26858309. Pmcid: PMC5278764.
  • McGraw KL, Nguyen J, Komrokji RS, Sallman D, Al Ali NH, Padron E, Lancet JE, Moscinski LC, List AF, Zhang L. Immunohistochemical pattern of p53 is a measure of TP53 mutation burden and adverse clinical outcome in myelodysplastic syndromes and secondary acute myeloid leukemia. Haematologica. 2016 Aug;101(8):e320-e323. Pubmedid: 27081179. Pmcid: PMC4967580.
  • Mughal TI, Cross NC, Padron E, Tiu RV, Savona M, Malcovati L, Tibes R, Komrokji RS, Kiladjian JJ, Garcia-Manero G, Orazi A, Mesa R, Maciejewski JP, Fenaux P, Itzykson R, Mufti G, Solary E, List AF. An International MDS/MPN Working Group's perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasms. Haematologica. 2015 Sep;100(9):1117-1130. Pubmedid: 26341525. Pmcid: PMC4800699.
  • Zeidan AM, Sekeres MA, Wang XF, Al Ali N, Garcia-Manero G, Steensma DP, Roboz G, Barnard J, Padron E, Dezern A, Maciejewski JP, List AF, Komrokji RS. Comparing the prognostic value of risk stratifying models for patients with lower-risk myelodysplastic syndromes: Is one model better?. Am J Hematol. 2015 Nov;90(11):1036-1040. Pubmedid: 26284571.
  • Zeidan AM, Al Ali NH, Padron E, Lancet J, List A, Komrokji RS. Lenalidomide Treatment for Lower Risk Nondeletion 5q Myelodysplastic Syndromes Patients Yields Higher Response Rates When Used Before Azacitidine. Clin Lymphoma Myeloma Leuk. 2015 Nov;15(11):705-710. Pubmedid: 26440749.
  • Savona MR, Malcovati L, Komrokji R, Tiu RV, Mughal TI, Orazi A, Kiladjian JJ, Padron E, Solary E, Tibes R, Itzykson R, Cazzola M, Mesa R, Maciejewski J, Fenaux P, Garcia-Manero G, Gerds A, Sanz G, Niemeyer CM, Cervantes F, Germing U, Cross NC, List AF. An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults. Blood. 2015 Mar;125(12):1857-1865. Pubmedid: 25624319. Pmcid: PMC4915792.
  • Padron E, Steensma DP. Cutting the cord from myelodysplastic syndromes: chronic myelomonocytic leukemia-specific biology and management strategies. Curr Opin Hematol. 2015 Mar;22(2):163-170. Pubmedid: 25575034.
  • Jabbour EJ, Garcia-Manero G, Strati P, Mishra A, Al Ali NH, Padron E, Lancet J, Kadia T, Daver N, O'Brien S, Steensma DP, Sekeres MA, Gore SD, Dezern A, Roboz GJ, List AF, Kantarjian HM, Komrokji RS. Outcome of patients with low-risk and intermediate-1-risk myelodysplastic syndrome after hypomethylating agent failure: a report on behalf of the MDS Clinical Research Consortium. Cancer. 2015 Mar;121(6):876-882. Pubmedid: 25410759. Pmcid: PMC4378905.
  • Zeidan AM, Gore SD, Padron E, Komrokji RS. Current state of prognostication and risk stratification in myelodysplastic syndromes. Curr Opin Hematol. 2015 Mar;22(2):146-154. Pubmedid: 25575032.
  • Sallman DA, Padron E. Transformation of the Clinical Management of CMML Patients Through In-Depth Molecular Characterization. Clin Lymphoma Myeloma Leuk. 2015 Jun;15 Suppl:S50-S55. Pubmedid: 26297278.
  • Komrokji R, Ramadan H, Al Ali N, Corrales-Yepez M, Zhang L, Padron E, Lancet J, List A. Validation of the Lower-Risk MD Anderson Prognostic Scoring System for Patients With Myelodysplastic Syndrome. Clin Lymphoma Myeloma Leuk. 2015 Jun;15 Suppl:S60-S63. Pubmedid: 26297280.
  • Chavez JC, Dalia S, Sandoval-Sus J, Kharfan-Dabaja MA, Al-Ali N, Komrokji R, Padron E, Corrales-Yepez G, Rock-Klotz J, Pinilla-Ibarz J. Second Myeloid Malignancies in a Large Cohort of Patients With Chronic Lymphocytic Leukemia: A Single Institution Experience. Clin Lymphoma Myeloma Leuk. 2015 Jun;15 Suppl:S14-S18. Pubmedid: 26297266.
  • Padron E, Garcia-Manero G, Patnaik MM, Itzykson R, Lasho T, Nazha A, Rampal RK, Sanchez ME, Jabbour E, Al Ali NH, Thompson Z, Colla S, Fenaux P, Kantarjian HM, Killick S, Sekeres MA, List AF, Onida F, Komrokji RS, Tefferi A, Solary E. An international data set for CMML validates prognostic scoring systems and demonstrates a need for novel prognostication strategies. Blood Cancer J. 2015 Jul;5:e333. Pubmedid: 26230957. Pmcid: PMC4526779.
  • Mishra A, Rollison DE, Brandon TH, Al Ali NH, Corrales-Yepez M, Padron E, Epling-Burnette PK, Lancet JE, List AF, Komrokji RS. Impact of tobacco usage on disease outcome in myelodysplastic syndromes. Leuk Res. 2015 Jul;39(7):673-678. Pubmedid: 25934048.
  • Zhang L, Padron E, Lancet J. The molecular basis and clinical significance of genetic mutations identified in myelodysplastic syndromes. Leuk Res. 2015 Jan;39(1):6-17. Pubmedid: 25465125.
  • Zeidan AM, Sekeres MA, Wang XF, Al Ali N, Garcia-Manero G, Steensma DP, Roboz G, Barnard J, Padron E, Dezern A, Maciejewski JP, List AF, Komrokji RS. Comparing the Prognostic Value of Risk stratifying Models for Patients with Lower-Risk Myelodysplastic Syndromes: Is one model better?. Am J Hematol. 2015 Aug. Pubmedid: 26260295. Pmcid: PMC4751065.
  • Bell GC, Padron E. Detection of a PDGFRB fusion in refractory CMML without eosinophilia: A case for broad spectrum tumor profiling. Leuk Res Rep. 2015;4(2):70-71. Pubmedid: 26716078. Pmcid: PMC4672079.
  • Padron E. Surveying the landscape of MDS/MPN research: overlap among the overlap syndromes?. Hematology Am Soc Hematol Educ Program. 2015;2015:349-354. Pubmedid: 26637742.
  • Peker D, Padron E, Bennett JM, Zhang X, Horna P, Epling-Burnette PK, Lancet JE, Pinilla-Ibarz J, Moscinski L, List AF, Komrokji RS, Zhang L. A close association of autoimmune-mediated processes and autoimmune disorders with chronic myelomonocytic leukemia: observation from a single institution. Acta Haematol. 2014 Nov;133(2):249-256. Pubmedid: 25413011.
  • Padron E, Komrokji R, List AF. The clinical management of chronic myelomonocytic leukemia. Clin Adv Hematol Oncol. 2014 Mar;12(3):172-178. Pubmedid: 24927265.
  • Padron E, Yoder S, Kunigal S, Mesa T, Teer JK, Al Ali N, Sekeres MA, Painter JS, Zhang L, Lancet J, Maciejewski JP, Epling-Burnette PK, Sotomayor E, Komrokji RS, List AF. ETV6 and signaling gene mutations are associated with secondary transformation of myelodysplastic syndromes to chronic myelomonocytic leukemia. Blood. 2014 Jun;123(23):3675-3677. Pubmedid: 24904105. Pmcid: PMC4047502.
  • Komrokji RS, Padron E, Yu D, Fulp WJ, Rodriguez Y, Tinsley S, List AF, Lancet JE. Phase II clinical study of erlotinib for treatment of myelodysplastic syndromes. Am J Hematol. 2014 Aug;89(8):809-812. Pubmedid: 24764152. Pmcid: PMC4561860.
  • Jaglal MV, Duong VH, Bello CM, Al Ali NH, Padron E, Fernandez HF, List AF, Lancet JE, Komrokji RS. Cladribine, cytarabine, filgrastim, and mitoxantrone (CLAG-M) compared to standard induction in acute myeloid leukemia from myelodysplastic syndrome after azanucleoside failure. Leuk Res. 2014 Apr;38(4):443-446. Pubmedid: 24439565.
  • McGraw KL, Basiorka AA, Johnson JO, Clark J, Caceres G, Padron E, Heaton R, Ozawa Y, Wei S, Sokol L, List AF. Lenalidomide induces lipid raft assembly to enhance erythropoietin receptor signaling in myelodysplastic syndrome progenitors. PLoS One. 2014;9(12):e114249. Pubmedid: 25469886. Pmcid: PMC4254997.
  • Komrokji RS, Padron E, Lancet JE, List AF. Prognostic factors and risk models in myelodysplastic syndromes. Clin Lymphoma Myeloma Leuk. 2013 Sep;13 Suppl 2:S295-S299. Pubmedid: 24290214.
  • Duong VH, Padron E, List AF, Komrokji RS. Multikinase inhibitors for treating high-risk myelodysplastic syndromes: can this be brought into clinical practice?. Expert Rev Hematol. 2013 Oct;6(5):485-487. Pubmedid: 24083503.
  • Padron E, Painter JS, Kunigal S, Mailloux AW, McGraw K, McDaniel JM, Kim E, Bebbington C, Baer M, Yarranton G, Lancet J, Komrokji RS, Abdel-Wahab O, List AF, Epling-Burnette PK. GM-CSF-dependent pSTAT5 sensitivity is a feature with therapeutic potential in chronic myelomonocytic leukemia. Blood. 2013 Jun;121(25):5068-5077. Pubmedid: 23632888. Pmcid: PMC4347259.
  • Mishra A, Corrales-Yepez M, Ali NA, Kharfan-Dabaja M, Padron E, Zhang L, Epling-Burnette PK, Pinilla-Ibarz J, Lancet JE, List AF, Komrokji RS. Validation of the revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes. Am J Hematol. 2013 Jul;88(7):566-570. Pubmedid: 23605934. Pmcid: PMC4685468.
  • Patnaik MM, Padron E, LaBorde RR, Lasho TL, Finke CM, Hanson CA, Hodnefield JM, Knudson RA, Ketterling RP, Al-kali A, Pardanani A, Ali NA, Komrokji RS, Komroji RS, Tefferi A. Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes. Leukemia. 2013 Jul;27(7):1504-1510. Pubmedid: 23531518.
  • Padron E, Abdel-Wahab O. Importance of genetics in the clinical management of chronic myelomonocytic leukemia. J Clin Oncol. 2013 Jul;31(19):2374-2376. Pubmedid: 23690427.
  • Komrokji RS, Padron E, Ebert BL, List AF. Deletion 5q MDS: molecular and therapeutic implications. Best Pract Res Clin Haematol. 2013 Dec;26(4):365-375. Pubmedid: 24507813.
  • Komrokji RS, Verstovsek S, Padron E, List AF. Advances in the management of myelofibrosis. Cancer Control. 2012 Oct;19(4 Suppl):4-15. Pubmedid: 23042420.
  • Komrokji RS, Corrales-Yepez M, Kharfan-Dabaja MA, Al Ali NH, Padron E, Rollison DE, Pinilla-Ibarz J, Zhang L, Epling-Burnette PK, Lancet JE, List AF. Hypoalbuminemia is an independent prognostic factor for overall survival in myelodysplastic syndromes. Am J Hematol. 2012 Nov;87(11):1006-1009. Pubmedid: 23090887.
  • Komrokji RS, Corrales-Yepez M, Al Ali N, Kharfan-Dabaja M, Padron E, Fields T, Lancet JE, List AF. Validation of the MD Anderson Prognostic Risk Model for patients with myelodysplastic syndrome. Cancer. 2012 May;118(10):2659-2664. Pubmedid: 21956402.
  • Sugimori C, Padron E, Caceres G, Shain K, Sokol L, Zhang L, Tiu R, O'Keefe CL, Afable M, Clemente M, Lee JM, Maciejewski JP, List AF, Epling-Burnette PK, Araten DJ. Paroxysmal nocturnal hemoglobinuria and concurrent JAK2(V617F) mutation. Blood Cancer J. 2012 Mar;2(3):e63. Pubmedid: 22829258. Pmcid: PMC3317526.
  • Padron E, Fernandez H. Anthracycline dose intensification in young adults with acute myeloid leukemia. Ther Adv Hematol. 2012 Feb;3(1):17-27. Pubmedid: 23556109. Pmcid: PMC3573430.
  • Padron E, Hazlehurst LE, Pinilla-Ibarz J. Molecular Pathogenesis of BCR-ABL in CML. Adv Malig Hematol. 2011 Mar;(62):71.
  • Padron E, Komrokji R, List AF. Biology and treatment of the 5q- syndrome. Expert Rev Hematol. 2011 Feb;4(1):61-69. Pubmedid: 21322779.
  • Padron E, Komrokji R, List AF. The 5q- syndrome: biology and treatment. CURR TREAT OPTION ON. 2011 Dec;12(4):354-368. Pubmedid: 21964863.

Provider

Eric Padron, MD

Medical Oncology

Call 1-888-Moffitt
(1-888-663-3488)
For an Appointment

Schedule Appointment

Program
Malignant Hematology

Print Print Physician Bio

Participating Trials

CLINICAL TRIAL 17929
A Phase I/II, Multicenter, Open-label, Dose Escalation and Randomized Trial of BI 836858 in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes
Condition: Malignant Hematology
Intervention: BI 836858
Open

CLINICAL TRIAL 18390
A Phase 1 Dose Escalation, Multicenter, Open-Label, Safety, Pharmacokinetic and Pharmacodynamic Study of FT-1101 In Patients With Relapsed or Refractory Hematologic Malignancies
Condition: Malignant Hematology
Intervention: FT-1101
Open

CLINICAL TRIAL 18563
A Randomized, Single-Blind, Multicenter Phase 2 Study to Evaluate the Activity of 2 Dose Levels of Imetelstat in Subjects with Intermediate-2 or High-Risk Myelofibrosis (MF)Relapsed/Refractory to Janus Kinase (JAK) Inhibitor
Condition: Malignant Hematology
Intervention: Imetelstat (GRN163L)
Open

CLINICAL TRIAL 17865
SL-401 in Patients with Acute Myeloid Leukemia or Blastic Plasmacytoid Dendritic Cell Neoplasm
Condition: Malignant Hematology
Intervention: SL-401
Open

CLINICAL TRIAL 18674
A Phase 2, Randomized, Controlled, Open-Label, Clinical Study of the Efficacy and Safety of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, and Low-Blast Acute Myelogenous Leukemia
Condition: Malignant Hematology
Intervention: MLN4924 (Pevonedistat); Pevonedistat; azacitidine (5-azacitidine)
Open

CLINICAL TRIAL 18434
A Phase 1/2a study of E6201 for the treatment of advanced hematologic malignancies with FLT3 and/or Ras mutations, including acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML)
Condition: Malignant Hematology
Intervention: E6201
Open

CLINICAL TRIAL 18083
Phase II Randomized Study of Lower Doses of Decitabine (DAC; 20 mg/m^2 IV daily for 3 days every month) versus Azacitidine (AZA; 75 mg/m^2 SC/IV daily for 3 days every month) versus Azcitidine (AZA; 75 mg/m^2 SC/IV daily for 5 days every month) in MDS Patients with Low and Intermediate-1 Risk Disease Transfusion-Dependent versus Best Supportive Care (BSC) in MDS Patients with Low and Intermediate-1 Risk Disease Transfusion-Independent
Condition: Malignant Hematology
Intervention: azacitidine (5-azacitidine); decitabine (5-aza-2'-deoxycytidine)
Open

CLINICAL TRIAL 18543
A Phase 3, Double-Blind, Randomized Study to Compare the Efficacy and Safety of Luspatercept(ACE-536) Versus Placebo for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndrome in Subjects with Ring Sideroblasts Who Require Red Blood Cell Transfusions
Condition: Malignant Hematology
Intervention: ACE-536 (Luspatercept); Luspatercept; Placebo
Open

CLINICAL TRIAL 18815
A Phase 2 Study of Tipifarnib in Subjects with Chronic Myelomonocytic Leukemia
Condition: Malignant Hematology
Intervention: Zarnestra (tipifarnib); tipifarnib
Open

CLINICAL TRIAL 18876
A Phase 1/1b Open-Label Study to Determine the Safety and Tolerability of ALRN-6924 alone and in Combination with Cytarabine (Ara-C) in Patients with Relapsed/Refractory Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome with Wild-Type TP53
Condition: Malignant Hematology
Intervention: ALRN-6924; Cytarabine (Cytosine Arabinoside)
Open

CLINICAL TRIAL 18406
A Phase 1 Study of AZD1775 in Combination with Belinostat in Relapsed and Refractory Myeloid Malignancies and Selected Untreated Patients with Acute Myeloid Leukemia
Condition: Malignant Hematology
Intervention: AZD1775; Belinostat; MK-1775 (AZD1775); PXD101 (Belinostat)
Open

CLINICAL TRIAL 18772
A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (>= 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)
Condition: Malignant Hematology
Intervention: Durvalumab; MEDI4736 (Durvalumab); azacitidine (5-azacitidine)
Open

CLINICAL TRIAL 18610
A Phase I-II Study of Triciribine Phosphate Monohydrate (PTX-200) Plus Cytarabine in Refractory or Relapsed Acute Leukemia
Condition: Malignant Hematology
Intervention: Cytarabine (Cytosine Arabinoside); PTX-200; Triciribine Phosphate monohydrate (PTX-200)
Open

CLINICAL TRIAL 18901
A Prospective, Open Label Phase I/II Study to Assess the Safety and Efficacy of Cycles of Intravenously Infused Doses of OPN-305 in Second-line Lower (Low and intermediate-1) Risk Myelodysplastic Syndrome (MDS)
Condition: Malignant Hematology
Intervention: OPN-305; azacitidine (5-azacitidine)
Open

If you believe you are eligible for one of these trials or studies, please call
1-888-MOFFITT (1-888-663-3488).


Provider

Eric Padron, MD

Medical Oncology

Call 1-888-Moffitt
(1-888-663-3488)
For an Appointment

Schedule Appointment

Program
Malignant Hematology

Print Print Physician Bio